Lung capillary injury and repair in left heart disease: A new target for therapy?

Clinical Science

Volumn 127, Issue 2, 2014, Pages 65-76

  Azarbar, Sayena ^a   Dupuis, Jocelyn ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

heart failure; left heart disease; pathophysiology; pulmonary heart disease; pulmonary hypertension

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BOSENTAN; DARUSENTAN; EPLERENONE; INSULIN; IRBESARTAN; ROSUVASTATIN; SILDENAFIL; SPIRONOLACTONE; TADALAFIL;

ARTICLE; CAPILLARY WALL; CORONARY ARTERY BLOOD FLOW; DIABETIC PATIENT; FLUID TRANSPORT; HEART DISEASE; HISTOPATHOLOGY; HUMAN; LEFT HEART DISEASE; LUNG ALVEOLUS WALL; LUNG CAPILLARY; LUNG CAPILLARY INJURY; LUNG INJURY; LUNG PARENCHYMA; LUNG STRUCTURE; MOLECULAR BIOLOGY; MYOFIBROBLAST; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY FUNCTION; AIRWAY REMODELING; ANIMAL; CAPILLARY; CAPILLARY PERMEABILITY; COMPLICATION; HEART DISEASES; LUNG; MORTALITY; PATHOLOGY; PHYSIOLOGY; PULMONARY HYPERTENSION; VASCULARIZATION;

AIRWAY REMODELING; ANIMALS; CAPILLARIES; CAPILLARY PERMEABILITY; HEART DISEASES; HUMANS; HYPERTENSION, PULMONARY; LUNG;

EID: 84897507072     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20130296     Document Type: Article

References (72)

1. West J. B. and Mathieu-Costello O. (1995) Vulnerability of pulmonary capillaries in heart disease. Circulation 92, 622-631.
2. Gehlbach B. K. and Geppert E. (2004) The pulmonary manifestations of left heart failure. Chest 125, 669-682.
3. Oudiz R. J. (2007) Pulmonary hypertension associated with left-sided heart disease. Clin. Chest Med. 28, 233-241.
4. Rich S. and Rabinovitch M. (2008) Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. Circulation 118, 2190-2199.
5. Abramson S. V., Burke J. F., Kelly, Jr J. J., Kitchen, III, J. G., Dougherty M. J., Yih D. F., McGeehin, III, F. C., Shuck J. W. and Phiambolis T. P. (1992) Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann. Intern. Med. 116, 888-895.
6. Bursi F., McNallan S. M., Redfield M. M., Nkomo V. T., Lam C. S., Weston S. A., Jiang R. and Roger V. L. (2012) Pulmonary pressures and death in heart failure: a community study. J. Am. Coll. Cardiol. 59, 222-231.
7. Delgado J. F., Conde E., Sanchez V., Lopez-Rios F., Gomez-Sanchez M. A., Escribano P., Sotelo T., Gomez de la Camara A., Cortina J. and de la Calzada C. S. (2005) Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur. J. Heart Fail. 7, 1011-1016.
8. Townsley M. I., Fu Z., Mathieu-Costello O. and West J. B. (1995) Pulmonary microvascular permeability. Responses to high vascular pressure after induction of pacing-induced heart failure in dogs. Circ. Res. 77, 317-325.
9. Guazzi M. (2003) Alveolar-capillary membrane dysfunction in heart failure: evidence of a pathophysiologic role. Chest 124, 1090-1102.
10. Guazzi M. (2008) Alveolar gas diffusion abnormalities in heart failure. J. Card. Fail. 14, 695-702.
11. Hummler E. and Planes C. (2010) Importance of ENaC-mediated sodium transport in alveolar fluid clearance using genetically-engineered mice. Cell Physiol. Biochem. 25, 63-70.
12. Guazzi M., Arena R. and Guazzi, MD. (2008) Evolving changes in lung interstitial fluid content after acute myocardial infarction: mechanisms and pathophysiological correlates. Am. J. Physiol. Heart Circ. Physiol. 294, H1357-H1364.
13. De Pasquale C. G., Arnolda L. F., Doyle I. R., Aylward P. E., Chew D. P. and Bersten A. D. (2004) Plasma surfactant protein-B: a novel biomarker in chronic heart failure. Circulation 110, 1091-1096.
14. Magri D., Brioschi M., Banfi C., Schmid J. P., Palermo P., Contini M., Apostolo A., Bussotti M., Tremoli E., Sciomer S. et al. (2009) Circulating plasma surfactant protein type B as biological marker of alveolar-capillary barrier damage in chronic heart failure. Circ. Heart Fail. 2, 175-180.
15. Ceridon M., Wanner A. and Johnson B. D. (2009) Does the bronchial circulation contribute to congestion in heart failure? Med. Hypotheses 73, 414-419.
16. Agostoni P. G., Doria E., Bortone F., Antona C. and Moruzzi P. (1995) Systemic to pulmonary bronchial blood flow in heart failure. Chest 107, 1247-1252.
17. Ceridon M. L., Morris N. R., Hulsebus M. L., Olson T. P., Lalande S. and Johnson B. D. (2011) Influence of bronchial blood flow and conductance on pulmonary function in stable systolic heart failure. Respir. Physiol. Neurobiol. 177, 256-264.
18. Ceridon M. L., Morris N. R., Olson T. P., Lalande S. and Johnson B. D. (2011) Effect of supine posture on airway blood flow and pulmonary function in stable heart failure. Respir. Physiol. Neurobiol. 178, 269-274.
19. Guazzi M., Pontone G., Brambilla R., Agostoni P. and Reina G. (2002) Alveolar-capillary membrane gas conductance: a novel prognostic indicator in chronic heart failure. Eur. Heart J. 23, 467-476.
20. Agostoni P., Bussotti M., Cattadori G., Margutti E., Contini M., Muratori M., Marenzi G. and Fiorentini C. (2006) Gas diffusion and alveolar-capillary unit in chronic heart failure. Eur. Heart J. 27, 2538-2543.
21. Guazzi M. (2012) Treating exercise oscillatory ventilation in heart failure: the detail that may matter. Eur. Respir. J. 40, 1075-1077.
22. Guazzi M., Cahalin L. P. and Arena R. (2013) Cardiopulmonary exercise testing as a diagnostic tool for the detection of left-sided pulmonary hypertension in heart failure. J. Card. Fail. 19, 461-467.
23. Guazzi M., Labate V., Cahalin L. P. and Arena R. (2013) Cardiopulmonary exercise testing reflects similar pathophysiology and disease severity in heart failure patients with reduced and preserved ejection fraction. Eur. J. Prev. Cardiol., doi: 10.1177/2047487313476962.
24. Sun X. G., Hansen J. E., Beshai J. F. and Wasserman K. (2010) Oscillatory breathing and exercise gas exchange abnormalities prognosticate early mortality and morbidity in heart failure. J. Am. Coll. Cardiol. 55, 1814-1823.
25. Agostoni P. G., Guazzi M., Bussotti M., Grazi M., Palermo P. and Marenzi G. (2000) Lack of improvement of lung diffusing capacity following fluid withdrawal by ultrafiltration in chronic heart failure. J. Am. Coll. Cardiol. 36, 1600-1604.
26. Mettauer B., Lampert E., Charloux A., Zhao Q. M., Epailly E., Oswald M., Frans A., Piquard F. and Lonsdorfer J. (1999) Lung membrane diffusing capacity, heart failure, and heart transplantation. Am. J. Cardiol. 83, 62-67.
27. Al-Rawas O. A., Carter R., Stevenson R. D., Naik S. K. and Wheatley D. J. (2000) The alveolar-capillary membrane diffusing capacity and the pulmonary capillary blood volume in heart transplant candidates. Heart 83, 156-160.
28. Dimopoulou I., Daganou M., Tsintzas O. K. and Tzelepis G. E. (1998) Effects of severity of long-standing congestive heart failure on pulmonary function. Respir. Med. 92, 1321-1325.
29. Kay J. M. and Edwards F. R. (1973) Ultrastructure of the alveolar-capillary wall in mitral stenosis. J. Pathol. 111, 239-245.
30. Kapanci Y., Burgan S., Pietra G. G., Conne B. and Gabbiani G. (1990) Modulation of actin isoform expression in alveolar myofibroblasts (contractile interstitial cells) during pulmonary hypertension. Am. J. Pathol. 136, 881-889.
31. Simonneau G., Robbins I. M., Beghetti M., Channick R. N., Delcroix M., Denton C. P., Elliott C. G., Gaine S. P., Gladwin M. T., Jing Z. C. et al. (2009) Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 54 (Suppl. 1), S43-S54.
32. Townsley M. I., Snell K. S., Ivey C. L., Culberson D. E., Liu D. C., Reed R. K. and Mathieu-Costello O. (1999) Remodeling of lung interstitium but not resistance vessels in canine pacing-induced heart failure. J. Appl. Physiol. 87, 1823-1830.
33. Ahmed M. S., Oie E., Vinge L. E., von Lueder T. G., Attramadal T. and Attramadal H. (2007) Induction of pulmonary connective tissue growth factor in heart failure is associated with pulmonary parenchymal and vascular remodeling. Cardiovasc. Res. 74, 323-333.
34. Kingsbury M. P., Huang W., Donnelly J. L., Jackson E., Needham E., Turner M. A. and Sheridan D. J. (2003) Structural remodelling of lungs in chronic heart failure. Basic Res. Cardiol. 98, 295-303.
35. Jasmin J. F., Calderone A., Leung T. K., Villeneuve L. and Dupuis J. (2003) Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan. Cardiovasc. Res. 58, 621-631.
36. Jiang B. H., Tardif, J-C., Sauvageau S., Ducharme A., Shi Y., Martin J. G. and Dupuis J. (2010) Beneficial effects of atorvastatin on lung structural remodeling and function in ischemic heart failure. J. Card. Fail. 16, 679-688.
37. Jiang B. H., Nguyen Q. T., Tardif, J-C., Shi Y. and Dupuis J. (2011) Single measurement of troponin T for early prediction of infarct size, congestive heart failure, and pulmonary hypertension in an animal model of myocardial infarction. Cardiovasc. Pathol. 20, e85-e89.
38. Cahalin L. P., Chase P., Arena R., Myers J., Bensimhon D., Peberdy M. A., Ashley E., West E., Forman D. E., Pinkstaff S. et al. (2013) A meta-analysis of the prognostic significance of cardiopulmonary exercise testing in patients with heart failure. Heart. Fail. Rev. 18, 79-94.
39. Huang W., Kingsbury M. P., Turner M. A., Donnelly J. L., Flores N. A. and Sheridan D. J. (2001) Capillary filtration is reduced in lungs adapted to chronic heart failure: morphological and haemodynamic correlates. Cardiovasc. Res. 49, 207-217.
40. Zhang K., Rekhter M. D., Gordon D. and Phan S. H. (1994) Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. Am. J. Pathol. 145, 114-125.
41. Hinz B., Phan S. H., Thannickal V. J., Galli A., Bochaton-Piallat M. L. and Gabbiani G. (2007) The myofibroblast: one function, multiple origins. Am. J. Pathol. 170, 1807-1816.
42. Epperly M. W., Guo H., Gretton J. E. and Greenberger J. S. (2003) Bone marrow origin of myofibroblasts in irradiation pulmonary fibrosis. Am. J. Respir. Cell. Mol. Biol. 29, 213-224.
43. Dupuis J., Prefontaine A., Villeneuve L., Ruel N., Lefebvre F. and Calderone A. (2007) Bone marrow-derived progenitor cells contribute to lung remodelling after myocardial infarction. Cardiovasc. Pathol. 16, 321-328.
44. Zeisberg M. and Kalluri R. (2004) The role of epithelial-to-mesenchymal transition in renal fibrosis. J. Mol. Med. 82, 175-181.
45. Kim K. K., Kugler M. C., Wolters P. J., Robillard L., Galvez M. G., Brumwell A. N., Sheppard D. and Chapman H. A. (2006) Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl. Acad. Sci. U.S.A. 103, 13180-13185.
46. Jasmin J. F., Mercier I., Hnasko R., Cheung M. W., Tanowitz H. B., Dupuis J. and Lisanti, MP. (2004) Lung remodeling and pulmonary hypertension after myocardial infarction: pathogenic role of reduced caveolin expression. Cardiovasc. Res. 63, 747-755.
47. Razani B., Engelman J. A., Wang X. B., Schubert W., Zhang X. L., Marks C. B., Macaluso F., Russell R. G., Li M., Pestell R. G. et al. (2001) Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 276, 38121-38138.
48. Razani B., Wang X. B., Engelman J. A., Battista M., Lagaud G., Zhang X. L., Kneitz B., Hou, Jr H., Christ G. J., Edelmann W. and Lisanti M. P. (2002) Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol. Cell Biol. 22, 2329-2344.
49. Guazzi M., Samaja M., Arena R., Vicenzi M. and Guazzi M. D. (2007) Long-term use of sildenafil in the therapeutic management of heart failure. J. Am. Coll. Cardiol. 50, 2136-2144.
50. Guazzi M., Vicenzi M., Arena R. and Guazzi M. D. (2011) PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ. Heart Fail. 4, 8-17.
51. Redfield M. M., Chen H. H., Borlaug B. A., Semigran M. J., Lee K. L., Lewis G., Lewinter M. M., Rouleau J. L., Bull D. A., Mann D. L. et al. (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309, 1268-1277.
52. Packer M., McMurray J., Massie B. M., Caspi A., Charlon V., Cohen-Solal A., Kiowski W., Kostuk W., Krum H., Levine B. et al. (2005) Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J. Card. Fail. 11, 12-20.
53. Packer M., Caspi A., Charlon V., Conen-Solal A., Kiowski W., Kostuk W., Krum H., Levine B., Massie B., McMurray J. et al. (1998) Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure-Results of the REACH-1 trial. Circulation 98, I-2.
54. Jiang B. H., Tardif, J-C., Shi Y. and Dupuis J. (2011) Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure. Eur. Respir. J. 37, 578-586.
55. Nguyen Q. T., Colombo F., Rouleau J. L., Dupuis J. and Calderone A. (2000) LU135252, an endothelin(A) receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarction. Br. J. Pharmacol. 130, 1525-1530.
56. Prie S., Leung T. K., Cernacek P., Ryan J. W. and Dupuis J. (1997) The orally active ETA receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J. Pharmacol. Exp. Ther. 282, 1312-1318.
57. Foody J. M., Shah R., Galusha D., Masoudi F. A., Havranek E. P. and Krumholz H. M. (2006) Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113, 1086-1092.
58. Go A. S., Lee W. Y., Yang J., Lo J. C. and Gurwitz J. H. (2006) Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 296, 2105-2111.
59. Tavazzi L., Maggioni A. P., Marchioli R., Barlera S., Franzosi M. G., Latini R., Lucci D., Nicolosi G. L., Porcu M. and Tognoni G. (2008) Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 1231-1239.
60. Kjekshus J., Apetrei E., Barrios V., Bohm M., Cleland J. G., Cornel J. H., Dunselman P., Fonseca C., Goudev A., Grande P. et al. (2007) Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 357, 2248-2261.
61. Imai Y., Kuba K., Rao S., Huan Y., Guo F., Guan B., Yang P., Sarao R., Wada T., Leong-Poi H. et al. (2005) Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112-116.
62. Guazzi M. and Agostoni P. (1999) Angiotensin-converting enzyme inhibition restores the diffusing capacity for carbon monoxide in patients with chronic heart failure by improving the molecular diffusion across the alveolar capillary membrane. Clin. Sci. 96, 17-22.
63. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J. and Gatlin M. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321.
64. Pitt B., Zannad F., Remme W. J., Cody R., Castaigne A., Perez A., Palensky J. and Wittes J. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709-717.
65. Zannad F., McMurray J. J., Krum H., van Veldhuisen D. J., Swedberg K., Shi H., Vincent J., Pocock S. J. and Pitt B. (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11-21.
66. Agostoni P., Magini A., Andreini D., Contini M., Apostolo A., Bussotti M., Cattadori G. and Palermo P. (2005) Spironolactone improves lung diffusion in chronic heart failure. Eur. Heart J. 26, 159-164.
67. Chabot A., Jiang B. H., Shi Y., Tardif, J-C. and Dupuis J. (2011) Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure. BMC Cardiovasc. Disord. 11, 72.
68. Agostoni P., Palermo P. and Contini M. (2009) Respiratory effects of β-blocker therapy in heart failure. Cardiovasc. Drugs Ther. 23, 377-384.
69. Guazzi M., Brambilla R., De Vita S. and Guazzi M. D. (2002) Diabetes worsens pulmonary diffusion in heart failure, and insulin counteracts this effect. Am. J. Respir. Crit. Care Med. 166, 978-982.
70. Guazzi M., Brambilla R., Pontone G., Agostoni P. and Guazzi M. D. (2002) Effect of non-insulin-dependent diabetes mellitus on pulmonary function and exercise tolerance in chronic congestive heart failure. Am. J. Cardiol. 89, 191-197.
71. Guazzi M., Oreglia I. and Guazzi M. D. (2002) Insulin improves alveolar-capillary membrane gas conductance in type 2 diabetes. Diabetes Care 25, 1802-1806.
72. Guazzi M., Arena R., Vicenzi M. and Guazzi M. D. (2009) Regulation of alveolar gas conductance by NO in man, as based on studies with NO donors and inhibitors of NO production. Acta Physiol. 196, 267-277.